Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws, including statements r

Redefining Neuroscience Drug

Development January 2025 Exhibit 99.1

Important Disclosures This

presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws, including statements related

to: Neumora's intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases; the timing,

progress and plans for its therapeutic development programs, including the timing of initiation and data read outs for its programs and studies, program milestones and potential value-creating catalysts, as well as its clinical trial and development

plans; future program guidance updates; timing and expectations related to regulatory filings and interactions; its potential to create significant value, probability of success with its proprietary approach and support for the development of its

programs; the market opportunity and therapeutic potential of its pipeline; the strength, scope and timing of its intellectual property protection; the safety profiles, differentiation, rationales and suitability for evaluation of navacaprant and

its other products candidates, and the probability of success of its study designs and execution; expectations and projections regarding future operating results and financial performance, including the sufficiency of its cash resources and timing

of its cash runway; and other statements identified by words such as "could," "expects," "intends," "may," "plans," "potential," "should," "will,"

"would," or similar expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this presentation are forward-looking statements within the meaning of the "safe harbor"

provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results to be materially different from the information expressed or implied by these

forward-looking statements, including, among others: the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation of,

enrollment in and any changes to our clinical trials, including slowing enrollment following topline KOASTAL-1 results and anticipated changes to our KOASTAL-2 and/or -3 stuides; risks related to our reliance on third parties, including CROs; risks

related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters that could affect sufficiency of capital resources to fund

operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora's business in general, please refer

to the risk factors identified in the Company's filings with the Securities and Exchange Commission (SEC), including but not limited to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 that was filed with the SEC on

November 12, 2024. Forward-looking statements speak only as of the date hereof, and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements.

Our Mission We are focused on

redefining neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases

Redefining Neuroscience Drug

Development Built at scale with strong balance sheet; $850M raised since 2021 Cash runway into mid-2026 supporting company growth World-class team with differentiated approach Maximizing probability of success with team and proprietary approach

Industry leading CNS pipeline with long-dated IP into the 2040s Multiple value-creating clinical catalysts expected in 2025

Navacaprant MDD Navacaprant BPD

NMRA-511 AD Agitation M4 PAM SCZ Navacaprant MDD Navacaprant BPD NMRA-511 AD Agitation Navacaprant MDD Navacaprant BPD Navacaprant MDD Neumora is Tackling One of the Largest Population Health Challenges 1National Institutes of Health. Our Biggest

Health Challenges. Accessed December 2023. Note: Figure not intended as launch guidance or order. BPD = Bipolar Depression; MDD = major depressive disorder. *Includes: MDD, BPD, Schizophrenia, Generalized Anxiety Disorder, Post Traumatic Stress

Disorder, Substance Use Disorder, Alzheimer's Disease, Parkinson's Disease, Attention-Deficit Hyperactivity Disorder Neumora's clinical-stage pipeline has potential to reach up to ~40M+ patients with a robust IP runway into 2041+ ~40M+ Patient

Opportunity 21M Patient Opportunity Biggest Health Disorders Facing U.S.1 Patients Impacted (M) Diabetes, Obesity & Metabolic Disease Neuropsychiatry & Neurodegenerative Disease* Infectious Disease Heart Disease & Stroke Traumatic Brain

Injury Cancer Neumora Focus Area Other Population Health Issue 0 20 40 60 80 100 120 140

PROGRAM Target/Mechanism INDICATION

U.S. Prevalence Preclinical Phase 1 Phase 2 Phase 3 MILESTONE Guidance Neuropsychiatry Programs Navacaprant (NMRA-140) KOR Antagonist Major Depressive Disorder 21M KOASTAL-2 and -3 topline data To be updated in 10-K Bipolar Depression 7M Phase 2

data 2H25 NMRA-511 V1aR Antagonist Agitation in Alzheimer's Disease 6M Phase 1b data 2H25 NMRA-266* M4 Modulator Schizophrenia 3M Provide update on clinical hold as available NMRA-M4R M4 Modulator Schizophrenia 3M Submit IND for next compound

1H25 NMRA-NMDA NMDA Modulator Schizophrenia 3M Neurodegeneration Programs NMRA-CK1 CK1 Inhibitor ALS/Alzheimer's Disease 25K/6M NMRA-NLRP3 NLRP3 Inhibitor Parkinson's Disease 1M NMRA-GCASE GCase Activator Parkinson's

Disease 1M Advancing a Leading Neuroscience Pipeline Broad pipeline addressing some of the most prevalent brain diseases Targeting novel mechanisms across a broad range of neuropsychiatric and neurodegenerative indications ALS = Amyotrophic lateral

sclerosis; CK1 = Casein Kinase I Isoform delta; GCase = Glucocerebrosidase; IP = Intellectual Property; KOR = kappa opioid receptor; M4R = Muscarinic Acetylcholine Receptor M4; NLRP3 = Nucleotide-binding Domain, Leucine-rich-containing

Family, Pyrin Domain-containing-3; NMDA = N-methyl-D-aspartate; V1aR = Vasopressin 1a Receptor. *Neumora announced on 4/15/24 that NMRA-266 is currently on clinical hold **All dates are approximate / estimates / projections only

Many people have inadequate response

to medication and experience tolerability issues MDD Represents a Major Population Health Challenge >70% of people with MDD experience anhedonia8 60-85% of patients treated with monotherapy9 21M adults in the U.S. have MDD2; the median

onset is ~32.5 years of age 1. World Health Organization. Depressive disorder (depression), Published March 31, 2023. Accessed June 5, 2024.

https://www.who.int/news-room/fact-sheets/detail/depression#:~:text=An%20estimated%203.8%25%20of%20the,world%20have%20depression%20(1). 2. National Institute of Mental Health. Major depression. Published January 2022. Accessed May 9, 2022.

https://www.nimh.nih.gov/health/statistics/major-depression. 3. Gaynes BN, et al. Cleve Clin J Med. 2008;75:57-66. 4. Corey-Lisle PK, et al. Arch Intern Med. 2004;164:1197-1204 5. Cartwright C, et al. Patient Prefer Adherence. 2016;10:1401-1407. 6.

Ramanuj P, et al. BMJ. 2019;365:I835. 7. Moret C, et al. J Psychopharmacol. 2009;23:967-974. 8. Khazanov GK, et al. Behav Res Ther. 2020;125:103507. 9. Kern et al. Treatment patterns and sequences of pharmacotherapy for patients diagnosed with

depression in the United States: 2014 through 2019. BMC Psychiatry. (2020) 20:4. ADT = antidepressant therapy; AE = adverse events 30 years since a novel mechanism of action was approved for MDD MDD is the leading cause of disability worldwide1 280M

people worldwide have MDD1 Many people have inadequate response to medication and experience tolerability issues 85% of patients either don't receive pharmacological treatment or fail to achieve remission with first-line

The Role of Kappa Opioid Receptor

Antagonism in MDD The kappa opioid receptor (KOR) / dynorphin system is a well-characterized pathway, and results from preclinical studies support its potential to modulate depression, anhedonia, and anxiety KOR system overactivation in response to

stress and mediation of depressive-like symptoms including anhedonia KOR antagonism may allow DA and 5HT release to return to adaptive levels during reward processing

Phase 2 Placebo-controlled RCT

evaluating efficacy and safety of navacaprant in patients with BPD Near-term Clinical Development Plan Focused on MDD and Bipolar Depression with Opportunity for Further Expansion Navacaprant Clinical Development Programs1 KOASTAL-1 Conducted in

U.S. Topline data announced Jan. 2025 KOASTAL-2 Conducted in U.S., Canada and Latin America KOASTAL-3 Conducted in U.S. and Europe KOASTAL-LT Open-label extension trial evaluating long-term safety of navacaprant in patients with MDD MDD = Major

Depressive Disorder; RCT = Randomized Controlled Trial; BPD = Bipolar Depression 1. Fourth pivotal study for navacaprant not included in current cash runway. Major Depressive Disorder Post-Traumatic Stress Disorder Generalized Anxiety Disorder ADHD

Substance Use Disorder Three replicate, placebo-controlled, double-blind RCTs evaluating efficacy and safety of navacaprant in MDD Bipolar Depression Additional Opportunities

KOASTAL Pivotal Study Design

Randomized, double-blind treatment Baseline WK 6 Navacaprant 80 mg QD Placebo QD R 1:1 Opportunity to enroll in KOASTAL-LT WK 1 WK 2 KOASTAL Pivotal Efficacy Studies KOASTAL-1, KOASTAL-2, KOASTAL-3 Summary Inclusion Criteria: Adults ages 18 -

65 diagnosed with MDD MADRS 25 at baseline Other Secondary Endpoints Include: from baseline to each timepoint in: CGI-S and CGI-I PHQ-9 HAM-A SDS Primary Endpoint: from baseline to Week 6 in MADRS total

score Key Secondary Endpoint: from baseline to Week 6 in SHAPS total score Key Exploratory Endpoints*: from baseline to each timepoint in: EQ-5D 5L WPAI-GH *Safety Assessments include Change in Sexual Functioning

Questionnaire (CSFQ-14) = Change; CGI-I = Clinical Global Impression-Improvement scale; CGI-S = Clinical Global Impression-Severity scale; EQ-5D 5L = EuroQol-5D 5L; HAM-A = Hamilton Anxiety Rating Scale; MADRS =

Montgomery- sberg Depression Rating Scale; MDD = Major Depressive Disorder; PHQ-9 = Patient Health Questionnaire-9; QD = once daily; SDS = Sheehan Disability Scale; SHAPS = Snaith-Hamilton Pleasure Scale; wk = week; WPAI-GH = Work Productivity

and Activity Impairment Questionnaire - General Health. Key Efficacy Assessments WK 4

KOASTAL-1 Topline Data:

Demographics and Baseline Characteristics Intent-to-Treat Population Navacaprant n = 191 Placebo N = 192 Age, mean (SD) 40.7 (14.0) 41.1 (13.2) Sex, n (%) Male Female 86 (45.0%) 105 (55.0%) 86 (44.8%) 106 (55.2%) Race, n (%) White Black or African

American Asian Other Missing/Unknown 112 (58.6%) 38 (19.9%) 25 (13.1%) 10 (5.2%) 6 (3.1%) 127 (66.1%) 31 (16.1%) 19 (9.9%) 10 (5.2%) 5 (2.6%) Baseline MADRS total score, mean (SD) 32.2 (4.2) 32.8 (4.7) Baseline SHAPS total score, mean (SD) 36.2

(6.2) 36.5 (6.7) MADRS = Montgomery- sberg Depression Rating Scale SHAPS = Snaith-Hamilton Pleasure Scale

KOASTAL-1 Topline Data: Primary

& Key Secondary Endpoint Improvement Improvement MADRS = Montgomery- sberg Depression Rating Scale SHAPS = Snaith-Hamilton Pleasure Scale

KOASTAL-1 Topline Data MADRS:

Efficacy Differences Observed Between Female and Male Participants Improvement Improvement ITT = Intent-to-Treat Population MADRS = Montgomery- sberg Depression Rating Scale SHAPS = Snaith-Hamilton Pleasure Scale

KOASTAL-1 Topline Data SHAPS:

Efficacy Differences Observed Between Female and Male Participants Improvement Improvement ITT = Intent-to-Treat Population MADRS = Montgomery- sberg Depression Rating Scale SHAPS = Snaith-Hamilton Pleasure Scale

KOASTAL-1 Topline Data: Favorable

Safety Profile Demonstrated Navacaprant was safe and generally well tolerated, with no serious adverse events reported No signal for increased suicidal ideation or suicidal behavior1 Low discontinuation rate due to TEAEs (navacaprant 2.1%; placebo

3.1%) 83.3% of navacaprant- treated patients who completed 6 weeks' treatment elected to enroll in KOASTAL-LT TEAEs Incidence (>2% in either treatment group) Placebo n=192 Navacaprant n=191 Preferred Terms n (%) n (%) Headache 14 (7.3%) 13

(6.8%) Diarrhea 4 (2.1%) 10 (5.2%) Nasopharyngitis 8 (4.2%) 7 (3.7%) Pruritus 4 (2.1%) 7 (3.7%) Nausea 6 (3.1%) 6 (3.1%) Constipation 6 (3.1%) 5 (2.6%) Insomnia 4 (2.1%) 3 (1.6%) Fatigue 9 (4.7%) 2 (1.0%) Upper respiratory tract infection 6 (3.1%) 2

(1.0%) Dizziness 5 (2.6%) 2 (1.0%) Dry mouth 4 (2.1%) 2 (1.0%) Somnolence 4 (2.1%) 2 (1.0%) Urinary tract infection 4 (2.1%) 2 (1.0%) Back pain 5 (2.6%) 0 1. As measured by Columbia Suicide Severity Rating Scale (C-SSRS)

Navacaprant Development Program Key

Learnings & Next Steps Neumora plans to provide additional information and update program guidance in 10-K KOASTAL-1 key learnings based on comprehensive analytics with topline data Potential adjustments to navacaprant development program Higher

placebo response rate than expected Males demonstrated especially high placebo response (14 points) and lower drug responses Encouraging trends in depressed mood and anhedonia in females Higher proportion of males in study (45%) relative to recent

comparable MDD studies (~30%) Navacaprant was well-tolerated with notable AEs (pruritus) observed Full dataset, including PK data, forthcoming for analysis Analyzing integrated data from Phase 2 and KOASTAL-1 (~600 patients) to inform predictors of

placebo response, drug/placebo difference and potential female/male differences for near-term adjustments to KOASTAL-2 and -3 Optimize site selection Enhance medical monitoring to identify optimal patients Assessing significance of sex-based

differences To date, KOASTAL-2 and -3 have enrolled more females than KOASTAL-1 Regulatory path for female-only development if warranted based on additional data ~70% of MDD prescriptions are written for females according to IQVIA

Navacaprant Well-Suited for

Evaluation in Bipolar Depression Signal-Seeking Study Designed to Efficiently Generate Data to Inform Development Path Randomized, double-blind treatment Baseline WK 6 Navacaprant 80 mg QD (n = 30) Placebo QD (n = 30) Bipolar II Depression

Signal-Seeking Study BIPOLAR II DEPRESSION SIGNAL-SEEKING STUDY Inclusion Criteria: Adults ages 18 - 65 experiencing an MDE associated with bipolar II depression MADRS 25 at baseline Primary Endpoint: from baseline to

Week 6 in MADRS total score Other Endpoints Include*: from baseline to Week 6 in: SHAPS total score PGIS-Anhedonia total score CGI-BP-S total score Statistics: Study not powered to demonstrate statistical significance Designed as a

signal-seeking study; effect size will inform the potential future development of navacaprant in bipolar depression *Safety Assessments include Columbia-Suicide Severity Rating Scale (C-SSRS), Young Mania Rating Scale (YMRS), Change in Sexual

Functioning Questionnaire (CSFQ-14) = Change; QD = once daily; MADRS = Montgomery- sberg Depression Rating Scale; SHAPS = Snaith-Hamilton Pleasure Scale; DARS = Dimensional Anhedonia Rating Scale; PGIS-Anhedonia = Patient

Global Impression of Severity - Anhedonia; CGI-BP-S = Clinical Global Impressions Scale for Use in Bipolar Illness - Severity 1Whitton AE., et al. 2023. 2Krystal, AD., et al. 2020. Depressed mood and anhedonia are highly prevalent and

clinically relevant symptoms in BPD1 Navacaprant has demonstrated efficacy in treating depressed mood and anhedonia in MDD in Phase 2 Results from this proof-of-concept study will inform further development of navacaprant in bipolar disorder

Potential to develop in broader bipolar disorder populations WK 2 WK 4 WK 1 Strong Rationale for Efficacy in Bipolar Depression R 1:1

Rationale Vasopressin plays a role

in the regulation of aggression, affiliation, stress and anxiety response Indication Agitation in Alzheimer's disease Status Phase 1b study underway with data anticipated in 2H25 Drug Profile Oral, BID dosing Strong IP Protection Expect

exclusivity through 2042+, based on composition of matter protection and estimated patent term extension NMRA-511 is a Best-in-Class Vasopressin 1a Receptor Antagonist with Broad Potential Across Neuropsychiatric Disorders

Alzheimer's Disease Agitation

Represents in Large Market Opportunity with Significant Unmet Need Agitation in Alzheimer's disease impacts a significant portion of the U.S. population; that number is expected to increase as the population ages1 1Alzheimer's

Association. Alzheimer's Disease Facts and Figures. May 2024. 2 Ijaopo et al., 2017., Translational Psychiatry.; 3Koenig et al., 2016, Current Psychiatry. Significant unmet medical need exists in this population3 Agitation is among the most

disruptive symptoms of AD. It is associated with greater caregiver stress, increased morbidity and mortality and earlier placement in long-term care facilities. The only currently approved product carries a black-box warning for mortality in elderly

people. ~7M 13M U.S. Adults with Alzheimer's Disease (M)1 >70% of people with AD experience agitation at some point in their disease2

Several Lines of Evidence Indicate

that V1a Receptor Antagonists Have Therapeutic Potential for Reducing Symptoms of Agitation In healthy volunteers, vasopressin enhances reactivity to threatening stimuli and disrupts emotional control1-2 Exogenously administered vasopressin

increases autonomic responsiveness to threat stimuli and increases anxiety2 V1a antagonist administration suppresses anxiety induced by unpredictable threats10 Positive association between vasopressin and aggression in people with personality